Oricell Therapeutics
About Oricell Therapeutics
Oricell Therapeutics is a biotechnology company focused on cancer immunotherapy, developing innovative cell therapies and antibody platforms. It operates with a global development approach, leveraging proprietary technologies to advance therapies for solid and hematologic malignancies, with activities centered in China and international collaborations. The company highlights its OriAb and OriCAR platforms, CAR-T programs such as OriCAR-017 and Ori-C101, and CMC capabilities to support clinical development and manufacturing. Its pipeline targets unmet clinical needs in cancers like multiple myeloma, liver cancer, and other solid tumors.
Recent News
Oricell Therapeutics Secures $110 Million Pre‑IPO Funding, Spotlighting Investment Banking Activity
Oricell Therapeutics Raises $110 Million to Advance Global Cell Therapy Development
Thomas Farrell
China-Based CAR-T Company Oricell Raises $40M More as It Looks to Go Public
Oricell Therapeutics Secures $110 Million to Take on One of Oncology's Most Vexing Problems
Oricell Closes a ‘Pre-IPO’ Megaround to Aim CAR-T at Solid Tumors
Oricell Therapeutics Secures $110 Million to Push GPC3‑Targeted CAR‑T for Liver Cancer
